XFOR Earnings Date: Nov 4, 2026 (Estimated) — X4 Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is XFOR's next earnings date?
X4 Pharmaceuticals, Inc. (XFOR) is expected to report Q3 2026 earnings on Wednesday, November 4, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.18 on revenue of $2.3M.
How did XFOR do in its last earnings report?
In its most recent report on Aug 7, 2026, X4 Pharmaceuticals, Inc. posted EPS of -$0.13 versus the -$0.18 estimate, a beat of 26.1%. Revenue was $8.8M against a $2.4M estimate. The stock's 1-day post-earnings move was +1.9%.
How much does XFOR stock move after earnings?
XFOR beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.2% (up or down) in the day after earnings.
About X4 Pharmaceuticals, Inc.
X4 Pharmaceuticals, Inc. is a biopharmaceutical firm committed to the discovery, development, and commercialization of innovative therapies for uncommon immune system disorders. Its primary drug candidate, XOLREMDI (also known as mavorixafor), is an orally administered, small-molecule antagonist specifically designed to target the chemokine receptor CXCR4. This compound is currently undergoing Phase 3 clinical trials for the management of WHIM syndrome, a rare immunodeficiency characterized by symptoms such as warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. To broaden its global presence, the company has entered into several licensing agreements: A partnership with Abbisko Therapeutics Co Ltd. grants rights for the manufacturing and distribution of XOLREMDI in mainland China, Taiwan, Hong Kong, and Macau. Another agreement with Norgine covers the development, production, and commercialization of mavorixafor across Europe, Australia, and New Zealand. Furthermore, X4 Pharmaceuticals holds a comprehensive agreement with Genzyme Corporation concerning the CXCR4 receptor, allowing for the development and commercialization of licensed compounds for all medical applications, including therapeutic, preventive, and diagnostic uses. The company maintains its corporate headquarters in Boston, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-07 | -0.18 | -0.13 | +26.14% | $8.8M | ✅ Beat | +1.92% | +2.88% | -3.12% | |
| 2026-08-06 | Q2 2026 | -0.19 | -0.13 | +31.58% | $8.8M | ✅ Beat | +11.27% | +2.88% | -3.12% |
| 2026-05-06 | Q1 2026 | -0.20 | -0.16 | +20.00% | $2.7M | ✅ Beat | +4.29% | +3.33% | -4.52% |
| 2026-03-17 | Q4 2025 | -0.35 | -0.22 | +37.14% | $2.6M | ✅ Beat | +18.82% | +14.33% | +21.63% |
| 2025-11-05 | Q3 2025 | -0.82 | -0.69 | +15.85% | $1.8M | ✅ Beat | -10.58% | -11.08% | -4.28% |
| 2025-08-08 | Q2 2025 | -1.86 | -3.47 | -86.56% | $2.0M | ❌ Miss | +2.05% | +115.07% | +132.19% |
| 2025-05-01 | Q1 2025 | -3.75 | 0.04 | +101.07% | $28.8M | ✅ Beat | -12.99% | -24.83% | -21.11% |
| 2025-03-25 | Q4 2024 | -0.16 | -0.20 | -25.00% | $1.4M | ❌ Miss | -12.07% | -19.86% | -31.76% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $8.8M total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| License and Other Revenue | 73.1% | $6.4M | +2709.2% | $27.9M | $229K | $199K | $297K |
| Product | 26.9% | $2.4M | -11.7% | $942K | $2.7M | $4.3M | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.